iShares Global Healthcare ETF IXJ

iShares Global Healthcare ETF (el Fondo), anteriormente conocido como iShares S&P Global Healthcare Sector Index Fund, es un fondo cotizado en bolsa (ETF). El Fondo busca resultados de inversión que se correspondan generalmente con el rendimiento del precio y el rendimiento por dividendos del S&P Global 1200 Healthcare Sector Index (el Índice). El Índice mide el rendimiento de empresas que Standards & Poor’s Financial Services LLC (S&P) considera parte del sector de bienes de consumo básico de la economía. Es un subconjunto del S&P Global 1200 Index. Las empresas componentes incluyen proveedores de servicios de salud, empresas de biotecnología y fabricantes de suministros médicos, dispositivos médicos avanzados y productos farmacéuticos. El Índice Subyacente está compuesto por acciones de empresas de países como Australia, Bélgica, Canadá, Dinamarca, Francia, Alemania, Irlanda, Japón, Países Bajos, Suiza, Reino Unido y Estados Unidos. El asesor de inversiones del Fondo es BlackRock Fund Advisors (BFA).

Con 10 acciones de IXJ (USD 1.007,60) habrías recibido USD 14,50 en dividendos en los últimos 12 meses.

• The Motley Fool 13 sept

  State Street XLV vs. iShares IXJ: Here's How These Healthcare ETFs Stack Up for Investors

  XLV and IXJ are two healthcare ETFs with different approaches: XLV focuses on 60 U.S. S&P 500 healthcare stocks with a low 0.08% expense ratio and stronger recent returns, while IXJ offers broader global diversification with 110 holdings across multiple countries but charges a higher 0.38% expense ratio. The choice depends on whether investors prioritize cost efficiency and domestic concentration or international diversification.

  

• The Motley Fool 8 ago

  iShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond?

  The article compares two healthcare-focused ETFs: iShares Global Healthcare ETF (IXJ) and State Street SPDR S&P Biotech ETF (XBI). XBI delivered superior 1-year returns of 80.2% with small-cap biotech focus but carries higher volatility (54% max drawdown). IXJ offers more stability with lower volatility, higher dividend yield (1.4%), and international diversification across large-cap pharmaceutical and healthcare companies. The analysis recommends XBI for long-term investors prioritizing performance despite greater risk.

  

• The Motley Fool 23 jul

  iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026?

  The article compares two healthcare-focused ETFs: iShares Global Healthcare ETF (IXJ) with 110 holdings offering global diversification and lower volatility, versus VanEck Biotech ETF (BBH) with 25 concentrated biotech positions delivering higher short-term returns but greater drawdown risk. IXJ is recommended for its superior long-term performance, geographic diversity, and stability despite BBH's impressive 30.8% one-year return.

  

• The Motley Fool 21 jul

  Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT?

  iShares Global Healthcare ETF (IXJ) offers broad diversification across 110 global healthcare companies with a lower 0.40% expense ratio, while First Trust NYSE Arca Biotechnology Index Fund (FBT) concentrates on 30 biotech companies with higher growth potential but greater volatility. IXJ suits defensive investors seeking stable exposure to established pharma giants, while FBT appeals to those betting on biotech breakthroughs despite higher risk.

  

• The Motley Fool 21 jul

  IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy?

  IXJ and RSPH are two healthcare ETFs with different strategies: IXJ uses cap-weighted global exposure with larger pharmaceutical companies, offering higher dividends (1.47%) and lower volatility (beta 0.52), while RSPH employs equal-weighting of S&P 500 healthcare stocks, providing stronger 1-year returns (21.01% vs 18.29%) but higher risk (beta 0.81). The choice depends on investor goals—IXJ suits conservative/income-focused investors, while RSPH appeals to growth-oriented investors willing to accept volatility.